Welcome to our dedicated page for Zenas BioPharma news (Ticker: ZBIO), a resource for investors and traders seeking the latest updates and insights on Zenas BioPharma stock.
Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company focused on autoimmune diseases, and its news flow reflects active development across multiple programs. Company announcements frequently highlight progress with its lead product candidate, obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb across the B cell lineage to inhibit cells implicated in autoimmune disease without depleting them. News items include updates on the Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease (IgG4-RD), Phase 2 MoonStone trial in Relapsing Multiple Sclerosis (RMS), and Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE), including reports of statistically significant efficacy results and safety findings.
Investors following ZBIO news can also track developments related to orelabrutinib, a late-stage, highly selective CNS-penetrant, oral BTK inhibitor licensed from InnoCare Pharma. Press releases cover Phase 3 trials in Primary Progressive Multiple Sclerosis (PPMS) and planned trials in Secondary Progressive Multiple Sclerosis (SPMS), as well as partner-reported data in SLE. Additional news covers earlier-stage programs ZB021 and ZB022, described as potentially best-in-class oral IL-17AA/AF and TYK2 inhibitors in IND-enabling or preclinical stages.
Regulatory, financing and corporate updates are another key component of Zenas BioPharma’s news. The company issues releases on revenue participation and funding agreements, such as its obexelimab funding arrangement with Royalty Pharma, private placement financings, and material license agreements with InnoCare. Earnings-related press releases and Form 8-K–linked announcements provide context on cash runway, research and development spending, and strategic priorities.
This ZBIO news page aggregates these disclosures so readers can follow clinical milestones, regulatory plans, licensing transactions and capital raises associated with Zenas’ autoimmune pipeline. For investors, analysts and healthcare professionals, it offers a single view into how obexelimab, orelabrutinib, ZB021 and ZB022 are progressing through development and how the company is structuring partnerships and funding to support its programs.
Zenas BioPharma (Nasdaq: ZBIO) announced a license agreement with InnoCare granting Zenas global MS and non-oncology rights to orelabrutinib plus rights to an oral IL-17AA/AF inhibitor and an oral, brain-penetrant TYK2 inhibitor. A global Phase 3 trial in PPMS has been initiated and a SPMS Phase 3 is expected to start in 1Q 2026. The two early candidates aim for IND/Phase 1 starts in 2026. Financial terms include up to $100M in upfront/near-term cash, up to 7.0M Zenas shares, total deal value exceeding $2B, and tiered royalties up to high‑teens. Zenas also announced a $120M private placement expected to close ~October 9, 2025, which it says funds operations into Q4 2026 (into Q1 2027 assuming a $75M milestone).
Zenas BioPharma (Nasdaq: ZBIO) has secured a funding agreement with Royalty Pharma (Nasdaq: RPRX) for up to $300 million to support the development and commercialization of obexelimab. The agreement includes an initial $75 million payment and three additional $75 million milestone payments tied to Phase 3 trial success, FDA approval for IgG4-RD, and FDA approval for SLE.
Obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, is currently in Phase 3 development for IgG4-Related Disease with results expected by year-end, and Phase 2 trials for Relapsing Multiple Sclerosis and Systemic Lupus Erythematosus. In exchange for funding, Royalty Pharma will receive a 5.5% royalty on worldwide net sales.
[ "Secured up to $300 million in funding for obexelimab development and commercialization", "Initial $75 million payment extends cash runway through Q1 2027", "Multiple near-term catalysts with Phase 3 IgG4-RD results expected year-end 2025", "Potential blockbuster opportunity in IgG4-RD market" ]Zenas BioPharma (NASDAQ:ZBIO), a clinical-stage biopharmaceutical company focused on autoimmune disease therapies, has announced its participation in three major healthcare investor conferences in September 2025.
The company will present at the Citi's 2025 Biopharma Back to School Conference (September 2), the Cantor Global Healthcare Conference (September 3), and the Morgan Stanley 23rd Annual Global Healthcare Conference (September 10). All presentations will be accessible via webcast on the company's website.
Zenas BioPharma (NASDAQ:ZBIO) has reported its Q2 2025 financial results and provided updates on its clinical programs. The company ended Q2 with $274.9 million in cash and investments, providing runway into Q4 2026.
Key clinical developments include: expected topline results from the Phase 3 INDIGO trial in IgG4-Related Disease by year-end 2025, completed enrollment in the Phase 2 MoonStone trial for Relapsing Multiple Sclerosis with results expected in early Q4 2025, and ongoing enrollment in the Phase 2 SunStone trial for Systemic Lupus Erythematosus with completion expected by year-end 2025.
Financial results show R&D expenses increased to $43.0 million from $33.8 million year-over-year, while G&A expenses rose to $12.1 million from $5.9 million. Net loss widened to $52.2 million compared to $38.0 million in Q2 2024.
Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage biopharmaceutical company focused on autoimmune disease therapies, has announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Thursday, June 5, 2025, at 1:25 p.m. ET. Interested parties can access both the live webcast and archived replay of the presentation through the "Events and Presentations" section of Zenas BioPharma's website under Investor & Media Relations.
Zenas BioPharma (Nasdaq: ZBIO) has announced key inducement grants for two newly appointed executives. The company's Compensation Committee approved non-qualified stock options on April 15, 2025, as part of their employment agreements.
Dr. Lisa von Moltke, appointed as Head of Research and Development and Chief Medical Officer, received options to purchase 400,000 shares. Dr. Haley Laken, the new Chief Scientific Officer, received options for 250,000 shares.
Both grants have a ten-year term with an exercise price of $8.72 per share, matching Zenas' closing stock price on the grant date. The options will vest over four years, with 25% vesting after one year of employment and the remainder vesting in 36 monthly installments, contingent on continued service.
Zenas BioPharma (Nasdaq: ZBIO) has appointed Haley Laken, Ph.D. as Chief Scientific Officer, bringing over 25 years of leadership experience in research and development. Dr. Laken will support the advancement of obexelimab, the company's B cell targeted therapy, through Phase 2 and Phase 3 clinical trials for treating IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Prior to joining Zenas, Dr. Laken served as Chief Operating Officer at Tabby Therapeutics, leading scientific initiatives and company operations. Her experience includes roles as Chief Development Officer at Jounce Therapeutics, senior program leadership at TESARO, and strategic positions at Rhythm Pharmaceuticals, Pfizer, and Wyeth.
Zenas BioPharma (Nasdaq: ZBIO) has appointed Lisa von Moltke, M.D. as Head of Research and Development and Chief Medical Officer. Dr. von Moltke brings over 30 years of drug development experience across multiple therapeutic areas.
The appointment comes as Zenas advances obexelimab through Phase 2 and Phase 3 clinical trials for autoimmune diseases, including IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. The drug's unique ability to inhibit B cells without depleting them, combined with its self-administered subcutaneous injection regimen, presents a promising treatment option.
Dr. von Moltke previously served as CMO at Seres Therapeutics and held senior positions at Alkermes, Sanofi/Genzyme, and Millennium. She completed a fellowship in clinical pharmacology at Tufts University and has served as President of the American College of Clinical Pharmacology.